Adults without health insurance are more likely to have undiagnosed hypercholesterolemia and hypertension than those with health insurance
NON-ELDERLY ADULTS without health insurance are far more likely to have undiagnosed-and consequently uncontrolled-hypercholesterolemia and hypertension than those with health insurance, according to a new analysis of Centers for Disease Control data.
"The analysis is really just one more indication of the many ways lack of health insurance is harmful to a person's health," says Andrew Wilper, MD, a professor in the Department of Medicine, University of Washington, who has conducted similar studies in the past.
The latest research, based on 2005-2008 data from the CDC's National Health and Nutrition Examination Survey (NHANES) found uninsured adults between the ages of 20 and 64 were about twice as likely to suffer from undiagnosed hypercholesterolemia or hypertension as their insured peers. In addition to interviews conducted in participants' homes, the NHANES survey includes standardized physical examinations conducted in mobile examination centers and laboratory tests utilizing blood and urine specimens provided by participants, which enable researchers to identify individuals with previously undiagnosed conditions.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes Under Way
April 23rd 2025Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read More